JP2018522891A - 凝集ペプチドを標的とする外傷性脳損傷の治療方法 - Google Patents

凝集ペプチドを標的とする外傷性脳損傷の治療方法 Download PDF

Info

Publication number
JP2018522891A
JP2018522891A JP2018503215A JP2018503215A JP2018522891A JP 2018522891 A JP2018522891 A JP 2018522891A JP 2018503215 A JP2018503215 A JP 2018503215A JP 2018503215 A JP2018503215 A JP 2018503215A JP 2018522891 A JP2018522891 A JP 2018522891A
Authority
JP
Japan
Prior art keywords
brain injury
traumatic brain
peptides
peptide
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018503215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522891A5 (cg-RX-API-DMAC7.html
Inventor
ランフェルト，ラース
バスン，ハンス
ロールマン ワーラ，エリク
ロールマン ワーラ，エリク
Original Assignee
バイオアークティック アーベー
バイオアークティック アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオアークティック アーベー, バイオアークティック アーベー filed Critical バイオアークティック アーベー
Publication of JP2018522891A publication Critical patent/JP2018522891A/ja
Publication of JP2018522891A5 publication Critical patent/JP2018522891A5/ja
Priority to JP2022079211A priority Critical patent/JP2022113682A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018503215A 2015-07-21 2016-07-20 凝集ペプチドを標的とする外傷性脳損傷の治療方法 Pending JP2018522891A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022079211A JP2022113682A (ja) 2015-07-21 2022-05-13 凝集ペプチドを標的とする外傷性脳損傷の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562195183P 2015-07-21 2015-07-21
US62/195,183 2015-07-21
US201662288813P 2016-01-29 2016-01-29
US62/288,813 2016-01-29
PCT/IB2016/054318 WO2017013599A1 (en) 2015-07-21 2016-07-20 Method for treatment of traumatic brain injury targeting aggregated peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022079211A Division JP2022113682A (ja) 2015-07-21 2022-05-13 凝集ペプチドを標的とする外傷性脳損傷の治療方法

Publications (2)

Publication Number Publication Date
JP2018522891A true JP2018522891A (ja) 2018-08-16
JP2018522891A5 JP2018522891A5 (cg-RX-API-DMAC7.html) 2019-08-15

Family

ID=56550266

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018503215A Pending JP2018522891A (ja) 2015-07-21 2016-07-20 凝集ペプチドを標的とする外傷性脳損傷の治療方法
JP2022079211A Pending JP2022113682A (ja) 2015-07-21 2022-05-13 凝集ペプチドを標的とする外傷性脳損傷の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022079211A Pending JP2022113682A (ja) 2015-07-21 2022-05-13 凝集ペプチドを標的とする外傷性脳損傷の治療方法

Country Status (7)

Country Link
US (1) US11327080B2 (cg-RX-API-DMAC7.html)
EP (1) EP3325506A1 (cg-RX-API-DMAC7.html)
JP (2) JP2018522891A (cg-RX-API-DMAC7.html)
CN (1) CN107849125A (cg-RX-API-DMAC7.html)
AU (1) AU2016295650A1 (cg-RX-API-DMAC7.html)
CA (1) CA2991856A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017013599A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
US11958896B2 (en) 2017-05-02 2024-04-16 Prothena Biosciences Limited Antibodies recognizing tau
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523764A (ja) * 2000-02-24 2003-08-12 ワシントン・ユニバーシティ Ａβペプチドを隔離するヒト化抗体
US20090074775A1 (en) * 2004-12-22 2009-03-19 David Michael Holtzman Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
JP2009530374A (ja) * 2006-03-23 2009-08-27 バイオアークティック ニューロサイエンス アーベー 改良型プロトフィブリル選択的抗体及びその使用
JP2013503201A (ja) * 2009-08-28 2013-01-31 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム タウオリゴマーに結合する抗体
WO2015035190A1 (en) * 2013-09-05 2015-03-12 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
WO2016005466A2 (en) * 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
WO2011001366A1 (en) 2009-06-29 2011-01-06 Bioartic Neuroscience Ab N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease
US10266585B2 (en) * 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
NO2539366T3 (cg-RX-API-DMAC7.html) 2010-02-26 2018-04-07
WO2012064836A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
WO2013168174A1 (en) 2012-05-08 2013-11-14 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
HK1215673A1 (zh) * 2012-12-07 2016-09-09 Biogen International Neuroscience Gmbh 一個使用抗ab抗體減少腦部澱粉蛋白質斑的方法
US20150126390A1 (en) * 2013-09-12 2015-05-07 Washington University Multiplex avidity profiling of protein aggregates

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523764A (ja) * 2000-02-24 2003-08-12 ワシントン・ユニバーシティ Ａβペプチドを隔離するヒト化抗体
US20090074775A1 (en) * 2004-12-22 2009-03-19 David Michael Holtzman Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
JP2009530374A (ja) * 2006-03-23 2009-08-27 バイオアークティック ニューロサイエンス アーベー 改良型プロトフィブリル選択的抗体及びその使用
JP2013503201A (ja) * 2009-08-28 2013-01-31 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム タウオリゴマーに結合する抗体
WO2015035190A1 (en) * 2013-09-05 2015-03-12 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
WO2016005466A2 (en) * 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FADEN ALAN I; LOANE DAVID J: "CHRONIC NEURODEGENERATION AFTER TRAUMATIC BRAIN INJURY: ALZHEIMER DISEASE, CHRONIC 以下備考", NEUROTHERAPEUTICS, vol. VOL:12, NR:1, JPN5018004341, 25 November 2014 (2014-11-25), US, pages 143 - 150, ISSN: 0004548174 *
HORI Y; ET AL: "ROLE OF APOLIPOPROTEIN E IN β-AMYLOIDOGENESIS: ISOFORM-SPECIFIC EFFECTS ON PROTOFIBRIL TO 以下備考", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. V.290 N.24, JPN5018004344, 12 June 2015 (2015-06-12), US, pages 15163 - 15174, ISSN: 0004548175 *
MAGNONI S; ET AL: "NEW PERSPECTIVES ON AMYLOID-BETA DYNAMICS AFTER ACUTE BRAIN INJURY: MOVING BETWEEN 以下備考", ARCHIVES OF NEUROLOGY, vol. V.67 N.9, JPN5018004340, September 2010 (2010-09-01), pages 1068 - 1073, ISSN: 0004548173 *

Also Published As

Publication number Publication date
US11327080B2 (en) 2022-05-10
US20180209994A1 (en) 2018-07-26
AU2016295650A1 (en) 2018-01-25
CN107849125A (zh) 2018-03-27
JP2022113682A (ja) 2022-08-04
EP3325506A1 (en) 2018-05-30
CA2991856A1 (en) 2017-01-26
WO2017013599A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
JP2022113682A (ja) 凝集ペプチドを標的とする外傷性脳損傷の治療方法
JP7421520B2 (ja) Ｔｐｐ１配合物及びｃｌｎ２疾患を治療するための方法
Zhao et al. β2-Microglobulin coaggregates with Aβ and contributes to amyloid pathology and cognitive deficits in Alzheimer’s disease model mice
Qureshi et al. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants
JP2019065029A (ja) 処置方法
KR20220084095A (ko) 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
Cisbani et al. Targeting innate immunity to protect and cure Alzheimer’s disease: opportunities and pitfalls
HK1258529A1 (zh) 用於治疗神经退行性和神经炎性病症的方法和组合物
JP2008501716A (ja) 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
EP2348042B1 (en) Modified amyloid beta peptide
Swanton et al. Is targeting the inflammasome a way forward for neuroscience drug discovery?
Panza et al. Passive tau-based immunotherapy for tauopathies
TW202035438A (zh) 阿茲海默症之判定藥及判定方法
JP2018516901A (ja) アミロイドβのガランタミンクリアランス
TW202325728A (zh) 治療阿茲海默症之方法
WO2015165980A2 (en) Treatment and prevention of alzheimer's disease (ad)
Hijioka et al. Multifactorial glial responses and their contributions to Alzheimer's disease continuum
Grange et al. Infliximab-induced cerebral thrombophlebitis
CN106794222A (zh) 使用p75ecd和/或p75诊断或治疗神经障碍的方法
US10889625B2 (en) Peptide-based methods for treating neurological injury
US20210187068A1 (en) Lipopolysaccharide-Binding Protein For Use In A Method Of Treating Alzheimer's Disease
TW202506139A (zh) 米韋爾西蘭（Ｍｉｖｅｌｓｉｒａｎ）組合物及其使用方法
Saxena et al. High-Mobility Group Box-1 and Its Potential Role in Perioperative Neurocognitive Disorders. Cells 2021, 10, 2582
TW202313111A (zh) 治療阿茲海默症之方法
Quesnel Insulin-like growth factor binding protein-2 and osteopontin in at-risk individuals with a parental history of Alzheimer’s disease and in autopsy-confirmed Alzheimer brains

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220513

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220517

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220602

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220607

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220624

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220628